Michael Aldridge - Executive Director   

Michael Aldridge, BSc (Hons), MAppFin - Executive Director
Mr Aldridge joined Xenome as Executive Director in March 2010.  He has an extensive background in the global biotechnology and pharmaceutical industries having held leadership, strategic, consulting and financing roles in North American, European and Australian companies. As CEO, Board Director and Consultant with Peplin, Inc. from October 2003, Michael led the growth of a global, dermatology focused, product company developing a new approach to the treatment of skin cancer. Peplin was sold to LEO Pharma A/S, a European dermatology company, for US$287.5 million in cash in September 2009. From September 2002 to September 2003, Mr. Aldridge served as a Director of Wilson HTM, an investment bank, in Brisbane, Australia. From 2000 to 2002, he served as an Associate Director of Bear, Stearns & Co.’s Healthcare Investment Banking Group. Prior to that, Mr. Aldridge held similar positions with Volpe Brown Whelan & Company in San Francisco and with the SG Warburg Group in Sydney and London. Mr. Aldridge received a B.S. in chemistry with honors from the University of Canterbury, New Zealand and an M.A. in applied finance from Macquarie University, Sydney, Australia.

 
Wendy Martin, MD – Chief Medical Officer
Dr Martin was trained as a neurologist has been a pharmaceutical physician since 1992 and has a strong technical background in international drug development from pre-clinical to Phase IV. She has therapeutic expertise related to the central nervous system, particularly analgesia and opiate drug development with successful regulatory approvals. Dr Martin has worked in large pharma, specialty mid-size pharma and biotechnology. Most recently she was VP of Global Product Development Services within an international contract research organization.